WuXi XDC Cayman Inc (HK:2268), a global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, announced on Monday that it has received multiple top awards in Extel's 2025 rankings.

The company was awarded 'Best CEO', 'Best CFO', 'Best Company Board', 'Best IR Program', 'Best IR Professional' and 'Best ESG (Environmental, Social and Governance)', in Extel's ranking of '2025 Asia (ex-Japan) Executive Team'.

Extel creates its research-supported rankings and names award recipients based on combined buy-side and sell-side surveys within the industry.

Michael Xi, CFO of WuXi XDC, said: "As a leading global CRDMO, we have been honored with multiple awards in the Extel Award for two consecutive years. This accomplishment signifies the international capital market's recognition of WuXi XDC's strategic positioning, corporate governance and social returns, and value creation capabilities.

"This award serves as both recognition and a responsibility. WuXi XDC will continue to foster a rewarding cycle of business growth and shareholder returns by maintaining deep market insights into bioconjugate development and enhancing global operational efficiency."